Gupta R K, Naran S
Department of Laboratory Services, Wellington Hospital and School of Medicine, New Zealand.
Acta Cytol. 1999 Mar-Apr;43(2):126-30. doi: 10.1159/000330965.
To analyze cases suggestive of cutaneous/subcutaneous metastatic deposits from a known carcinoma or as the first manifestation of an unknown carcinoma using fine needle aspiration cytology (FNAC).
The study group consisted of 146 patients (86 males and 60 females) ranging in age from 34 to 82 years. In 135 cases there was a previous history of carcinoma, and in these cases FNAC showed the tumor to be similar to the carcinoma that had been treated by surgery and/or radiotherapy. In 11 patients no tumor had been found previously, and the site of the unknown primary was suggested by immunostaining. Aspirations were performed using a 22-gauge needle. The material was collected in 30% ethyl alcohol, and filter preparations and cell blocks were made.
The size of metastatic nodules ranged from 1.5 to 2 cm. The sites of metastases were on the chest wall (n = 35), back (n = 8), abdomen (including umbilicus) (n = 46), head and neck (n = 35), upper extremity (n = 12), lower extremity ((n = 6), penile skin (n = 1) and vulva (n = 3). The sites of known primary carcinomas were breast (n = 39), lung (n = 35), gastrointestinal tract (n = 38), endometrium (n = 2), cervix (n = 3), urinary tract (n = 4), prostate (n = 3), hand (n = 1), scalp (n = 1), tongue (n = 1), brain (n = 1), ear (n = 3) and ovary (n = 4). The sites of primary carcinomas unknown at the time of aspiration and found after FNAC were the gastrointestinal tract (n = 3), lung (n = 2), prostate (n = 1), breast (n = 3), liver (n = 1) and kidney (n = 1). No false negatives or positives were observed, and no second primary tumors were found. Cytologic preparations were sufficient for diagnosis and typing in tumors with a known primary tumor. Immunostaining was helpful in establishing a diagnosis of carcinoma and in determining the likely primary site in tumors with unknown primaries.
Cutaneous and subcutaneous metastatic deposits from previously known carcinomas can be diagnosed rapidly and accurately utilizing FNAC. A combination of FNAC and immunostaining may also help define the site of an unknown primary.
运用细针穿刺细胞学检查(FNAC)分析提示为已知癌的皮肤/皮下转移灶或作为未知癌首发表现的病例。
研究组由146例患者组成(男性86例,女性60例),年龄在34至82岁之间。135例患者有癌病史,在这些病例中,FNAC显示肿瘤与经手术和/或放疗治疗过的癌相似。11例患者此前未发现肿瘤,通过免疫染色提示了未知原发灶的部位。使用22号针进行穿刺。将材料收集于30%乙醇中,并制作过滤涂片和细胞块。
转移结节大小为1.5至2厘米。转移部位为胸壁(n = 35)、背部(n = 8)、腹部(包括脐部)(n = 46)、头颈部(n = 35)、上肢(n = 12)、下肢(n = 6)、阴茎皮肤(n = 1)和外阴(n = 3)。已知原发癌的部位为乳腺(n = 39)、肺(n = 35)、胃肠道(n = 38)、子宫内膜(n = 2)、宫颈(n = 3)、泌尿道(n = 4)、前列腺(n = 3)、手部(n = 1)、头皮(n = 1)、舌部(n = 1)、脑(n = 1)、耳部(n = 3)和卵巢(n = 4)。穿刺时未知但FNAC后发现的原发癌部位为胃肠道(n = 3)、肺(n = 2)、前列腺(n = 1)、乳腺(n = 3)、肝脏(n = 1)和肾脏(n = 1)。未观察到假阴性或假阳性,也未发现第二原发肿瘤。细胞学涂片足以对已知原发肿瘤的肿瘤进行诊断和分型。免疫染色有助于确诊癌并确定未知原发肿瘤的可能原发部位。
利用FNAC可快速、准确地诊断已知癌的皮肤和皮下转移灶。FNAC与免疫染色相结合也可能有助于确定未知原发灶的部位。